Long Islanders suffering from sleep apnea inundated the sleep center at St. Charles Hospital in Port Jefferson with phone ...

Apnimed's experimental drug reduced breathing interruptions by nearly 46.8% in clinical trials, offering a potential ...

The first oral pill for obstructive sleep apnea could be around the corner after company Apnimed reported positive results ...

In today’s Health Alert, obstructive sleep apnea may soon be treated with a simple, once-a-day pill. This first-in-class oral ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

Obstructive sleep apnea is still largely undiagnosed and untreated. In a growing marketplace of solutions, can negative pressure devices compete?

Content by Advanced Dental Sleep Treatment Center. Thankfully, there is a treatment that’s effective, sustainable and noninvasive: an oral appliance worn at night.

Obstructive sleep apnea (OSA) was associated with a significantly increased risk for adverse health outcomes and healthcare resource use among military personnel in the US, according to data from ...

If you're one of the roughly 30 million Americans with sleep apnea, mouth taping could seriously restrict airflow, thus depriving your brain and body of critically needed oxygen, according to experts.

Eli Lilly and Novo Nordisk NVO presently dominate this space. Mounjaro and Zepbound directly compete with Novo Nordisk’s semaglutide medicines, Ozempic for diabetes and Wegovy for obesity.

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.